Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Breast Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 911Carboplatin 788pembrolizumab 749Paclitaxel 745Bevacizumab 717Cisplatin 709Gemcitabine 621Docetaxel 585Rituximab 559Radiotherapy 548Dexamethasone 512Nivolumab 492Doxorubicin 446Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 328Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × MM-111 × Clear all
NCT01774851 2017-06-22

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Merrimack Pharmaceuticals

Phase 2 Terminated
84 enrolled 10 charts
Gastrointestinal

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT00911898 2015-01-13

Monotherapy

Merrimack Pharmaceuticals

Phase 1 Completed
20 enrolled 5 charts
Breast

Breast Neoplasms

NCT01097460 2015-01-07

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
16 enrolled 7 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡